A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network

A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network

ABSTRACT Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults, characterized by the accumulation of dysfunctional lymphocytes. Ibrutinib, a first‐generation Bruton tyrosine kinase (BTK) inhibitor, has significantly improved CLL treatment but is associated with adverse car...

Full description

Saved in:
Bibliographic Details
Main Authors: Abdulrahman Majrashi, Ying X. Gue, Alena Shantsila, Stella Williams, Catrin Tudur Smith, Gregory Y. H. Lip, Andrew R. Pettitt
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Pharmacology Research & Perspectives
Subjects:
acalabrutinib
atrial fibrillation
cardiovascular toxicities
hypertension
ibrutinib
Online Access:https://doi.org/10.1002/prp2.70113
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items